
Search Clinical Trials
Below please find a list of studies actively recruiting volunteers at one of the following GHUCCTS institutions: Georgetown University, Howard University, MedStar Health Research Institute, or Washington DC VA Medical Center. Please enter your search criteria below to help find a study for you. If you have any questions, please email us or call us at 301-560-2963.
Study is registered in ResearchMatch ![]() Sponsor Condition of Interest |
---|
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
![]()
University of Southern California
Mild Cognitive Impairment (MCI)
Alzheimer's Disease (AD)
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging
Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD.
ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been
combined... expand
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research. Type: Observational Start Date: Oct 2016 |
Transcranial Direct Current Stimulation for Post-stroke Motor Recovery
![]()
Duke University
Stroke, Ischemic
Motor Activity
Upper Extremity Paralysis
This research study is to find out if brain stimulation at different dosage level combined
with an efficacy-proven rehabilitation therapy can improve arm function. The stimulation
technique is called transcranial direct current stimulation (tDCS). The treatment uses direct... expand
This research study is to find out if brain stimulation at different dosage level combined with an efficacy-proven rehabilitation therapy can improve arm function. The stimulation technique is called transcranial direct current stimulation (tDCS). The treatment uses direct currents to stimulate specific parts of the brain affected by stroke. The adjunctive rehabilitation therapy is called "modified Constraint-Induced Movement Therapy" (mCIMT). During this therapy the subject will wear a mitt on the hand of the arm that was not affected by a stroke and force to use the weak arm. The study will test 3 different doses of brain stimulation in combination with mCIMT to find out the most promising one. Type: Interventional Start Date: Sep 2019 |
Memory Improvement Through Nicotine Dosing (MIND) Study
![]()
University of Southern California
Mild Cognitive Impairment
The purpose of the study is to see if daily transdermal nicotine is able to produce a
significant cognitive, clinical and functional improvement in participants with MCI. Neuronal
nicotinic receptors have long been known to play a critical role in memory function in
preclinical... expand
The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function. The study will enroll 300 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch. Type: Interventional Start Date: Jan 2017 |
A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for...
![]()
Merz Pharmaceuticals GmbH
Essential Tremor of the Upper Limb
The purpose of this study is to determine whether a single treatment with administration of
NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of
essential tremor in the arm (Unilateral Period). Participants will be assigned to the
treatment... expand
The purpose of this study is to determine whether a single treatment with administration of NT 201 (botulinum toxin) is superior to placebo (no medicine) for one-sided treatment of essential tremor in the arm (Unilateral Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation. The following treatment cycle will investigate the safety and tolerability of two-sided treatment with NT 201 (botulinum toxin) (Open Label Bliaterial Period). All participants will receive NT 201 treatment. Type: Interventional Start Date: Feb 2021 |
Study to Assess the Effectiveness and Safety of Lenacapavir for Human Immunodeficiency Virus (HIV) Pre-Exposure...
![]()
Gilead Sciences
Pre-Exposure Prophylaxis of HIV Infection
The primary objective of this study is to evaluate the efficacy of lenacapavir (LEN) in
preventing the risk of human immunodeficiency virus (HIV) - 1 infection relative to the
background HIV-1 incidence rate.
The study will be conducted in 2 parts: a cross-sectional study... expand
The primary objective of this study is to evaluate the efficacy of lenacapavir (LEN) in preventing the risk of human immunodeficiency virus (HIV) - 1 infection relative to the background HIV-1 incidence rate. The study will be conducted in 2 parts: a cross-sectional study (Incidence Phase) and a double-blind, randomized study (Randomized Phase). The Incidence Phase will include initial assessments that will provide an estimate of the concurrent background HIV-1 incidence rate. The Randomized Phase of the study will have a Blinded Phase, a LEN Open-label Extension (OLE) Phase, and a pharmacokinetic (PK) Tail Phase. The primary objective for the Incidence Phase of this study is to estimate the HIV-1 background incidence rate. The primary objective of the Randomized Blinded Phase of this study is to evaluate the efficacy of lenacapavir for HIV-1 pre-exposure prophylaxis (PrEP) in cisgender men (CGM), transgender women (TGW), transgender men (TGM), and gender nonbinary people (GNB) ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection. Type: Interventional Start Date: Jun 2021 |
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants...
![]()
Eisai Inc.
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
The primary purpose of this study is to determine whether treatment with lecanemab is
superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite
5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with
lecanemab... expand
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). Type: Interventional Start Date: Jul 2020 |
Technical Development of Cardiovascular Magnetic Resonance Imaging
National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Disease
Background:
In the U.S., over 6.5 million people have heart failure. Researchers want to develop new
testing methods for cardiovascular problems using magnetic resonance imaging (MRI) to improve
the clinical diagnosis and management of people with heart failure.... expand
Background: In the U.S., over 6.5 million people have heart failure. Researchers want to develop new testing methods for cardiovascular problems using magnetic resonance imaging (MRI) to improve the clinical diagnosis and management of people with heart failure. Objective: To develop and test new methods for imaging the heart and blood vessels using MRI. Eligibility: People ages 18 years and older who are having an MRI of their heart or blood vessels. Healthy volunteers are also needed. Design: Participants will be screened with a medical history. Participants will have a physical exam and blood tests. They will have an electrocardiogram (ECG) to measure the heart s electrical activity. Then they will have their scheduled MRI scan. The MRI scanner is a large, hollow tube. Participants will lie on a table that moves in and out of the tube. During the MRI, they may have contrast dye injected through an intravenous line inserted into their arm or hand. ECG may be used to monitor their heartbeat or coordinate pictures with their heartbeat. A flexible belt may be used to monitor their breathing. A finger probe may be used to track their heart rate and/or oxygenation level. Their blood pressure may be measured. Pictures may be taken of their blood vessels, heart, and lungs before, during, and after they get medicine to increase blood flow. They may lie flat and pedal a stress bicycle to increase their heart rate. Participation will last for 5 years. During that time, participants may receive a yearly survey about their health. They may be contacted for an optional follow-up MRI within 2 years of their MRI. Type: Observational Start Date: Sep 2021 |
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease 2019
Background:
COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the
number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell
that fights infections. With fewer lymphocytes, the body cannot effectively fight... expand
Background: COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections. With fewer lymphocytes, the body cannot effectively fight back against SARS CoV-2, the virus that causes COVID-19. Researchers want to better understand how SARS-CoV-2 affects these blood cells. This information may give them ideas for new treatments. Objective: To learn more about how SARS-CoV-2 affects lymphocytes, the immune, and the blood clotting system. Eligibility: Adults age 18 and older who either currently have COVID-19 or have recently recovered from it Design: Participants will give a blood sample. For this, a needle is used to collect blood from an arm vein. For participants who have a central line, blood will be collected through that instead. Participants medical records related to COVID-19 will be reviewed. Participants who have recovered from COVID-19 will be asked to undergo leukapheresis to collect white blood cells. For this, blood is taken from a needle placed in one arm. A machine separates out the white blood cells. The rest of the blood is returned to the participant through a needle placed in the other arm. This takes about 2-3 hours. Recovered participants may have material collected from inside the nostrils and/or rectum. This is done by gently rubbing the area with a sterile cotton swab. Recovered participants may have an echocardiogram to look at their heart. For this, a small probe is held against the chest to get pictures of the heart from different angles. This takes less than 30 minutes. Participation lasts 1-2 days on most cases and may be split in a few visits for recovered patients if leukapheresis and echocardiogram are done. ... Type: Observational Start Date: May 2020 |
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients...
Hoffmann-La Roche
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
The main objective of the study is to evaluate the efficacy of satralizumab compared with
placebo based on time from randomization to the first occurrence of an adjudicated MOGAD
relapse in the double-blind (DB) treatment period
expand
The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occurrence of an adjudicated MOGAD relapse in the double-blind (DB) treatment period Type: Interventional Start Date: Sep 2022 |
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab,...
Hoffmann-La Roche
Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate the surgical safety and feasibility of atezolizumab plus tiragolumab
alone or in combination with platinum-based chemotherapy as neoadjuvant treatment for
participants with previously untreated locally advanced non-small cell lung cancer (NSCLC).
The... expand
This study will evaluate the surgical safety and feasibility of atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as neoadjuvant treatment for participants with previously untreated locally advanced non-small cell lung cancer (NSCLC). The study will also evaluate the efficacy, pharmacokinetics, immunogenicity, and safety of atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by adjuvant atezolizumab plus tiragolumab or adjuvant platinum-based chemotherapy. Type: Interventional Start Date: Apr 2021 |
Open-label, Follow-up of Doravirine/Islatravir for Participants With Human Immunodeficiency Virus -1...
Merck Sharp & Dohme LLC
HIV-1 Infection
The safety and tolerability of MK-8591A, a novel 2-drug fixed dose combination (FDC) of
doravirine (DOR) and islatravir (ISL) will be evaluated in adult and pediatric participants
with Human Immunodeficiency Virus -1 (HIV-1) who were treated with DOR and ISL in earlier
clinical... expand
The safety and tolerability of MK-8591A, a novel 2-drug fixed dose combination (FDC) of doravirine (DOR) and islatravir (ISL) will be evaluated in adult and pediatric participants with Human Immunodeficiency Virus -1 (HIV-1) who were treated with DOR and ISL in earlier clinical studies. Type: Interventional Start Date: Sep 2021 |
Efficacy and Safety of MK-1654 in Infants (MK-1654-004)
Merck Sharp & Dohme LLC
Respiratory Syncytial Virus Infection
The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study
are to evaluate the efficacy and safety of MK-1654 in healthy pre-term and full-term infants.
It is hypothesized that MK-1654 will reduce the incidence of respiratory syncytial virus... expand
The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of MK-1654 in healthy pre-term and full-term infants. It is hypothesized that MK-1654 will reduce the incidence of respiratory syncytial virus (RSV)-associated medically attended lower respiratory infection (MALRI) from Days 1 through 150 postdose compared to placebo. Type: Interventional Start Date: Apr 2021 |
Abbreviated Protocol for Two-Stage Exchange
Osteal Therapeutics, Inc.
Prosthetic Joint Infection
Study Type: A multi-site, parallel group, randomized trial.
Study Objectives: The objective is to evaluate safety and determine preliminary efficacy of
VT-X7. Efficacy is evaluated as superiority of the Experimental Arm in a composite endpoint
of Overall Success at 90 days,... expand
Study Type: A multi-site, parallel group, randomized trial. Study Objectives: The objective is to evaluate safety and determine preliminary efficacy of VT-X7. Efficacy is evaluated as superiority of the Experimental Arm in a composite endpoint of Overall Success at 90 days, consisting of a revision prosthesis implanted at Stage 2, patient survival, absence of reoperation and absence of PJI. Secondary objectives are to evaluate superiority at 365 days in a composite endpoint of Overall Success, and in separate secondary endpoints for quality of life (QoL) and patient survival. The exploratory objective is to compare Experimental and Control Arms in exploratory endpoints. Follow-up: Patients will be evaluated at 90-, 180-, and 365-day follow-up visits. Type: Interventional Start Date: Nov 2021 |
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive...
Daiichi Sankyo, Inc.
HER2-Positive Primary Breast Cancer
Residual Invasive Breast Cancer
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response
after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More
effective treatment options are needed for this patient population. This study will examine
the... expand
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy. Type: Interventional Start Date: Dec 2020 |
Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-Threatening Bleeding...
PhaseBio Pharmaceuticals Inc.
Hemorrhage
Urgent Surgery
Invasive Procedure
This is a multi-center, open-label, prospective single-arm study of reversal of the
antiplatelet effects of ticagrelor with bentracimab (PB2452) in patients who present with
uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive
procedure.... expand
This is a multi-center, open-label, prospective single-arm study of reversal of the antiplatelet effects of ticagrelor with bentracimab (PB2452) in patients who present with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure. Approximately 200 patients will be enrolled from approximately 200 centers in North America, Europe, and Asia-Pacific regions, including mainland China. Patients with reported use of ticagrelor within the prior 3 days who require urgent ticagrelor reversal will be eligible for enrollment. These populations will be enrolled based on separate inclusion criteria. Type: Interventional Start Date: Mar 2020 |
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal...
Alliance for Clinical Trials in Oncology
Colorectal Adenocarcinoma
This phase III trial studies how well vitamin D3 given with standard chemotherapy and
bevacizumab works in treating patients with colorectal cancer that has spread to other parts
of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and
teeth.... expand
This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body. Vitamin D3 helps the body use calcium and phosphorus to make strong bones and teeth. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, oxaliplatin, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving vitamin D3 with chemotherapy and bevacizumab may work better in shrinking or stabilizing colorectal cancer. It is not yet known whether giving high-dose vitamin D3 in addition to chemotherapy and bevacizumab would extend patients' time without disease compared to the usual approach (chemotherapy and bevacizumab). Type: Interventional Start Date: Sep 2019 |
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
Natera, Inc.
Kidney Transplant Rejection
The ProActive registry is a longitudinal, multi-center study with a prospective arm observing
clinical care for patients receiving physician ordered Prospera, an allograft rejection test,
and a historical control arm collecting data on cases at the same sites whose kidney... expand
The ProActive registry is a longitudinal, multi-center study with a prospective arm observing clinical care for patients receiving physician ordered Prospera, an allograft rejection test, and a historical control arm collecting data on cases at the same sites whose kidney allograft rejection status was managed with Serum Creatinine SCr/estimated Glomerular Filtration Rate eGFR. This registry will compare patient management and outcomes in patients who receive Prospera (Prospera arm) to the outcomes of the historical control group (control arm) to determine Prospera's clinical utility. High-risk subjects defined as having a biopsy-demonstrated rejection event or at least one pre-existing Donor Specific Antibody DSA with total Mean Fluorescent Intensity MFI>3000 or a calculated Panel Reactive Antibodies cPRA>70% will be followed for an additional period up to 24 months in both the Prospera arm and historical control arm. Type: Observational [Patient Registry] Start Date: Nov 2019 |
Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer
Alliance for Clinical Trials in Oncology
Malignant Neoplasm
Surgical Procedure, Unspecified
Health Care Provider
Carcinoma
This trial studies how well the use of a pre-surgical toolkit (OPTI-Surg) works in improving
surgical care and outcomes in older participants with cancer. In many elderly patients,
surgery can greatly affect physical condition and the ability to return to pre-surgery levels... expand
This trial studies how well the use of a pre-surgical toolkit (OPTI-Surg) works in improving surgical care and outcomes in older participants with cancer. In many elderly patients, surgery can greatly affect physical condition and the ability to return to pre-surgery levels of physical functioning. Providing pre-surgical recommendations may help improve participants' recovery rate and functioning after surgery. Type: Interventional Start Date: Apr 2019 |
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe...
Medtronic Cardiovascular
Mitral Valve Regurgitation
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All
subjects enrolled with receive the study device.
expand
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device. Type: Interventional Start Date: Oct 2017 |
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3...
Turning Point Therapeutics, Inc.
Locally Advanced Solid Tumors
Metastatic Solid Tumors
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the
maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose
(RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an... expand
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Type: Interventional Start Date: Feb 2017 |
Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving...
University of California, San Francisco
Stage IA Breast Cancer
Stage IIA Breast Cancer
This phase IV trial studies the side effects of intraoperative radiation therapy and how well
it works in treating patients with breast cancer undergoing breast-conserving surgery.
Delivering radiation one time to the area where the tumor was removed while the patient is
still... expand
This phase IV trial studies the side effects of intraoperative radiation therapy and how well it works in treating patients with breast cancer undergoing breast-conserving surgery. Delivering radiation one time to the area where the tumor was removed while the patient is still in the operating room may kill any residual tumor cells and may be as effective as standard radiation therapy in patients with early stage breast cancer. Type: Interventional Start Date: May 2012 |
Natural History of Stroke: Cause and Development
National Institute of Neurological Disorders and Stroke (NINDS)
Brain Disease
Ischemic Attack, Transient
Cerebrovascular Accident
Cerebrovascular Disorder
Vascular Diseases
The purpose of this study is to learn more about stroke and obtain information that may serve
as the basis for future investigations. It will 1) establish a registry of patients with
cerebrovascular disease (stroke); 2) characterize the natural history of acute stroke and... expand
The purpose of this study is to learn more about stroke and obtain information that may serve as the basis for future investigations. It will 1) establish a registry of patients with cerebrovascular disease (stroke); 2) characterize the natural history of acute stroke and transient ischemic attacks (TIA) an interruption of blood flow to the brain that causes stroke symptoms for a short period of time); and 3) evaluate the data to generate ideas for future studies. Patients 18 years of age or older with suspected acute stroke or TIA may be eligible for this study. Subjects will be recruited from patients who present with stroke at the emergency department of Suburban Hospital in Bethesda, Maryland. The study will gather data collected from diagnostic and laboratory tests the patient undergoes as part of standard medical care, including findings of medical and neurological examinations and other tests. In addition, studies will be done for research purposes only to gather data about stroke and TIA. These may include the following: - Blood and urine tests not more than 2 tablespoons of blood will be drawn for various tests. - Electrocardiogram (EKG) (heart tracing) electrodes placed on the chest wall detect the heartbeat and heart rhythm. - Computed tomography (CT) scan of the head specialized X-rays are used to obtain images of the brain. - Magnetic resonance imaging (MRI) of the brain a strong magnetic field and radio waves are used to produce images that provide information about the brain tissue and blood vessels. - Transcranial Doppler (TCD) sound waves are used to image the arteries of the brain and neck. - Echocardiogram sound waves are used to image the heart and evaluate heart function. Patients may be asked to return to Suburban Hospital for follow-up testing in 1, 3, and/or 12 months, when some of these tests may be repeated to assess changes over time ... Type: Observational Start Date: Jan 2001 |
MANTA Ultrasound Closure Study
Essential Medical, Inc.
Femoral Arteriotomy Closure
Demonstrate the safety of MANTA Vascular Closure Device (VCD) ultrasound (U/S) guided closure
in patients undergoing elective TAVR procedures with planned percutaneous femoral arterial
access.
expand
Demonstrate the safety of MANTA Vascular Closure Device (VCD) ultrasound (U/S) guided closure in patients undergoing elective TAVR procedures with planned percutaneous femoral arterial access. Type: Interventional Start Date: Aug 2022 |
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.
Perimeter Medical Imaging
Breast Cancer
This is a multi-center, randomized, two-arm study designed to measure the effectiveness of
the SELENE system in reducing the number of unaddressed positive margins in breast lumpectomy
procedures when used in addition to standard intraoperative margin assessment.
expand
This is a multi-center, randomized, two-arm study designed to measure the effectiveness of the SELENE system in reducing the number of unaddressed positive margins in breast lumpectomy procedures when used in addition to standard intraoperative margin assessment. Type: Interventional Start Date: Dec 2021 |
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic...
Mirum Pharmaceuticals, Inc.
Progressive Familial Intrahepatic Cholestasis
Alagille Syndrome
Cholestatic Liver Disease
This study is designed to assess whether the investigational drug maralixibat, is safe and
well tolerated in children <12 months of age with Alagille Syndrome [ALGS] or Progressive
Familial Intrahepatic Cholestasis [PFIC].
expand
This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in children <12 months of age with Alagille Syndrome [ALGS] or Progressive Familial Intrahepatic Cholestasis [PFIC]. Type: Interventional Start Date: Sep 2021 |